Roger Chou
Auto-generated profile, based on publicly available information

Roger Chou

Oregon Health & Science University, Portland, Oregon (R.C.)

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2016 in JAMA
Verified
Journal Article
Open access
PDF file
DDDeborah Dowell
Deborah Dowell
THTamara M. Haegerich
Tamara M. Haegerich
RCRoger Chou
Roger Chou
The number of people experiencing chronic pain is substantial, with US prevalence estimated at 11.2% of the adult population.1 Patients should receive appropriate pain treatment based on a careful consideration of the benefits and risks of treatment options. Opioids are commonly prescribed for pain, with approximately 3% to 4% of the adult US population prescribed long-term opioid therapy.2 Evidence supports short-term efficacy of opioids in randomized clinical trials lasting primarily 12 weeks or less,3 and patients receiving opioid therapy for chronic pain report some pain relief when surveyed.4-6 However, few studies have been conducted to rigorously assess the long-term benefits of opioids for chronic pain (pain lasting >3 months) with outcomes examined at least 1 year later.7 Opioid pain medication use presents serious risks. From 1999 to 2014, more than 165 000 persons died of overdose related to opioid pain medication in the United States.8 In 2013 alone, an estimated 1.9 million persons abused or were dependent on prescription opioid pain medication.9 Primary care clinicians report concern about opioid pain medication misuse, find managing patients with chronic pain stressful, express concern about patient addiction, and report insufficient training in prescribing opioids.10

1 February 2016 in The Journal of Pain
Verified
Journal Article
Closed access
RCRoger Chou
Roger Chou
DGDebra B. Gordon
Debra B. Gordon
OLOscar A. de Leon-Casasola
Oscar A. de Leon-Casasola
JRJack M. Rosenberg
Jack M. Rosenberg
SBStephen Bickler
Stephen Bickler
CWChristopher L. Wu
Christopher L. Wu

2 October 2007 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
RCRoger Chou
Roger Chou
AQAmir Qaseem
Amir Qaseem
VSVincenza Snow
Vincenza Snow
DCDonald Casey
Donald Casey
JCJ. Thomas Cross
J. Thomas Cross
FPfor the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel*
for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel*
Clinicians should conduct a focused history and physical examination to help place patients with low back pain into 1 of 3 broad categories: nonspecific low back pain, back pain potentially associated with radiculopathy or spinal stenosis, or back pain potentially associated with another specific spinal cause. The history should include assessment of psychosocial risk factors, which predict risk for chronic disabling back pain (strong recommendation, moderate-quality evidence). Clinicians should not routinely obtain imaging or other diagnostic tests in patients with nonspecific low back pain (strong recommendation, moderate-quality evidence). Clinicians should perform diagnostic imaging and testing for patients with low back pain when severe or progressive neurologic deficits are present or when serious underlying conditions are suspected on the basis of history and physical examination (strong recommendation, moderate-quality evidence). Clinicians should evaluate patients with persistent low back pain and signs or symptoms of radiculopathy or spinal stenosis with magnetic resonance imaging (preferred) or computed tomography only if they are potential candidates for surgery or epidural steroid injection (for suspected radiculopathy) (strong recommendation, moderate-quality evidence). Clinicians should provide patients with evidence-based information on low back pain with regard to their expected course, advise patients to remain active, and provide information about effective self-care options (strong recommendation, moderate-quality evidence). For patients with low back pain, clinicians should consider the use of medications with proven benefits in conjunction with back care information and self-care. Clinicians should assess severity of baseline pain and functional deficits, potential benefits, risks, and relative lack of long-term efficacy and safety data before initiating therapy (strong recommendation, moderate-quality evidence). For most patients, first-line medication options are acetaminophen or nonsteroidal anti-inflammatory drugs. For patients who do not improve with self-care options, clinicians should consider the addition of nonpharmacologic therapy with proven benefits—for acute low back pain, spinal manipulation; for chronic or subacute low back pain, intensive interdisciplinary rehabilitation, exercise therapy, acupuncture, massage therapy, spinal manipulation, yoga, cognitive-behavioral therapy, or progressive relaxation (weak recommendation, moderate-quality evidence). * This paper, written by Roger Chou, MD; Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Donald Casey, MD, MPH, MBA; J. Thomas Cross Jr., MD, MPH; Paul Shekelle, MD, PhD; and Douglas K. Owens, MD, MS, was developed for the American College of Physicians' Clinical Efficacy Assessment Subcommittee and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel. For members of these groups, see end of text. Approved by the American College of Physicians Board of Regents on 14 July 2007. Approved by the American Pain Society Board Executive Committee on 18 July 2007.

1 June 2018 in The Lancet
Verified
Journal Article
Closed access
NFNadine E Foster
Nadine E Foster
JAJohannes R Anema
Johannes R Anema
DCDan Cherkin
Dan Cherkin
RCRoger Chou
Roger Chou
Douglas Paul GrossDouglas Paul Gross
Douglas Paul Gross
AWAnthony Woolf
Anthony Woolf

1 February 2009 in The Journal of Pain
Verified
Journal Article
Closed access
RCRoger Chou
Roger Chou
GFGilbert J. Fanciullo
Gilbert J. Fanciullo
PFPerry G. Fine
Perry G. Fine
JAJeremy A. Adler
Jeremy A. Adler
JBJane C. Ballantyne
Jane C. Ballantyne
CMChristine Miaskowski
Christine Miaskowski

17 February 2015 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RCRoger Chou
Roger Chou
JTJudith A. Turner
Judith A. Turner
EDEmily B. Devine
Emily B. Devine
RHRyan N. Hansen
Ryan N. Hansen
SSSean D. Sullivan
Sean D. Sullivan
RDRichard A. Deyo
Richard A. Deyo
Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness. To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic pain in adults. MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, PsycINFO, and CINAHL (January 2008 through August 2014); relevant studies from a prior review; reference lists; and ClinicalTrials.gov. Randomized trials and observational studies that involved adults with chronic pain who were prescribed long-term opioid therapy and that evaluated opioid therapy versus placebo, no opioid, or nonopioid therapy; different opioid dosing strategies; or risk mitigation strategies. Dual extraction and quality assessment. No study of opioid therapy versus no opioid therapy evaluated long-term (>1 year) outcomes related to pain, function, quality of life, opioid abuse, or addiction. Good- and fair-quality observational studies suggest that opioid therapy for chronic pain is associated with increased risk for overdose, opioid abuse, fractures, myocardial infarction, and markers of sexual dysfunction, although there are few studies for each of these outcomes; for some harms, higher doses are associated with increased risk. Evidence on the effectiveness and harms of different opioid dosing and risk mitigation strategies is limited. Non–English-language articles were excluded, meta-analysis could not be done, and publication bias could not be assessed. No placebo-controlled trials met inclusion criteria, evidence was lacking for many comparisons and outcomes, and observational studies were limited in their ability to address potential confounding. Evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Evidence supports a dose-dependent risk for serious harms. Agency for Healthcare Research and Quality.